Global Anti-Dermatomycosis Treatment Market 2024 by Company, Regions, Type and Application, Forecast to 2030
Page: 136
Published Date: 10 Jan 2024
Category: Medical Devices & Consumables
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
According to our (Global Info Research) latest study, the global Anti-Dermatomycosis Treatment market size was valued at USD 4002.6 million in 2023 and is forecast to a readjusted size of USD 5992 million by 2030 with a CAGR of 5.9% during review period.
Dermatomycosis are infections of skin, nails, and hair which are caused by dermatophytes, yeasts and moulds.Anti-fungals are grouped in to three classes based on action like azoles (inhibit synthesis of Ergosterol), Polyenes (membrane sterols), and 5-Fluorocytosine (inhibits macromolecular synthesis).
The global anti-dermatomycosis treatment market refers to the overall market for medications and therapies used in the treatment of dermatomycosis, which is a fungal infection of the skin. Dermatomycosis, also known as tinea or ringworm, can affect various parts of the body, including the scalp, body, groin, feet, and nails.
The market for anti-dermatomycosis treatment has been growing steadily due to factors such as the increasing prevalence of fungal infections, rising awareness, and the development of effective antifungal therapies. Dermatomycosis is a common condition, particularly in tropical and subtropical regions, and can affect individuals of all ages.
The market is segmented based on various factors, including product type, route of administration, distribution channel, and geography. Different types of anti-dermatomycosis treatments include topical antifungal creams, oral antifungal medications, and, in severe cases, intravenous antifungal therapies.
Topical antifungal creams are commonly used as first-line treatments for dermatomycosis and are available over the counter or by prescription. Oral antifungal medications, such as azoles, allylamines, and griseofulvin, are prescribed for more severe or widespread infections or those that do not respond to topical treatments. In some cases, combination therapy may be used to enhance efficacy.
The market is also influenced by the distribution channel, with anti-dermatomycosis treatments being available in retail pharmacies, hospital pharmacies, and online platforms. The choice of distribution channel may depend on factors such as the severity of the infection, prescription requirements, and consumer preferences.
Geographically, the market is divided into regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The Asia Pacific region, including countries like India and China, is expected to witness significant growth in the market due to a high burden of fungal infections and a large population.
Key factors driving the growth of the global anti-dermatomycosis treatment market include the increasing prevalence of fungal infections, the growing adoption of antifungal therapies, the development of novel treatment options, and the efforts of pharmaceutical companies to expand their product portfolios.
Key players in the market include pharmaceutical companies, biotechnology firms, and research organizations. These companies invest in research and development, clinical trials, and collaborations to develop new antifungal therapies and enhance existing treatment options.
Market dynamics, growth rates, and the competitive landscape may vary across regions and specific antifungal product types. Factors such as drug resistance, regulatory approvals, pricing, and reimbursement policies can influence the market dynamics.
In summary, the global anti-dermatomycosis treatment market is witnessing steady growth due to the increasing prevalence of fungal infections and the development of effective antifungal therapies. However, market conditions and growth rates may be influenced by factors like the emergence of drug-resistant strains, regulatory challenges, competitive landscape, and access to healthcare services.
The Global Info Research report includes an overview of the development of the Anti-Dermatomycosis Treatment industry chain, the market status of Tinea Corporis (Polyens, Azoles), Tinea Unguium (Polyens, Azoles), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Anti-Dermatomycosis Treatment.
Regionally, the report analyzes the Anti-Dermatomycosis Treatment markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Anti-Dermatomycosis Treatment market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Anti-Dermatomycosis Treatment market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Anti-Dermatomycosis Treatment industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Polyens, Azoles).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Anti-Dermatomycosis Treatment market.
Regional Analysis: The report involves examining the Anti-Dermatomycosis Treatment market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Anti-Dermatomycosis Treatment market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Anti-Dermatomycosis Treatment:
Company Analysis: Report covers individual Anti-Dermatomycosis Treatment players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Anti-Dermatomycosis Treatment This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Tinea Corporis, Tinea Unguium).
Technology Analysis: Report covers specific technologies relevant to Anti-Dermatomycosis Treatment. It assesses the current state, advancements, and potential future developments in Anti-Dermatomycosis Treatment areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Anti-Dermatomycosis Treatment market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Anti-Dermatomycosis Treatment market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Polyens
Azoles
Allylamines
Echinocandins
Others
Market segment by Application
Tinea Corporis
Tinea Unguium
Aspergillosis
Tinea Capitis
Others
Market segment by players, this report covers
Pfizer Inc.
Sanofi S.A.
Novatis AG
Mylan N.V.
Abbott Laboratories
Bayer AG
Eli Lilly and Company
AbbVie Inc.
Glaxosmithkline Plc
Janssen Pharmaceuticals, Inc.
Taro Pharmaceutical Industries Ltd.
Mayne Pharma Group Limited
Viamet Pharmaceuticals, Inc.
Scynexis Inc.
Enzon Pharmaceuticals
Gilead Sciences Inc.
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Anti-Dermatomycosis Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Anti-Dermatomycosis Treatment, with revenue, gross margin and global market share of Anti-Dermatomycosis Treatment from 2019 to 2024.
Chapter 3, the Anti-Dermatomycosis Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Anti-Dermatomycosis Treatment market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Anti-Dermatomycosis Treatment.
Chapter 13, to describe Anti-Dermatomycosis Treatment research findings and conclusion.
Table of Contents
1 Market Overview
1.1 Product Overview and Scope of Anti-Dermatomycosis Treatment
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Anti-Dermatomycosis Treatment by Type
1.3.1 Overview: Global Anti-Dermatomycosis Treatment Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Anti-Dermatomycosis Treatment Consumption Value Market Share by Type in 2023
1.3.3 Polyens
1.3.4 Azoles
1.3.5 Allylamines
1.3.6 Echinocandins
1.3.7 Others
1.4 Global Anti-Dermatomycosis Treatment Market by Application
1.4.1 Overview: Global Anti-Dermatomycosis Treatment Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Tinea Corporis
1.4.3 Tinea Unguium
1.4.4 Aspergillosis
1.4.5 Tinea Capitis
1.4.6 Others
1.5 Global Anti-Dermatomycosis Treatment Market Size & Forecast
1.6 Global Anti-Dermatomycosis Treatment Market Size and Forecast by Region
1.6.1 Global Anti-Dermatomycosis Treatment Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Anti-Dermatomycosis Treatment Market Size by Region, (2019-2030)
1.6.3 North America Anti-Dermatomycosis Treatment Market Size and Prospect (2019-2030)
1.6.4 Europe Anti-Dermatomycosis Treatment Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Anti-Dermatomycosis Treatment Market Size and Prospect (2019-2030)
1.6.6 South America Anti-Dermatomycosis Treatment Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Anti-Dermatomycosis Treatment Market Size and Prospect (2019-2030)
2.1 Pfizer Inc.
2.1.1 Pfizer Inc. Details
2.1.2 Pfizer Inc. Major Business
2.1.3 Pfizer Inc. Anti-Dermatomycosis Treatment Product and Solutions
2.1.4 Pfizer Inc. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Pfizer Inc. Recent Developments and Future Plans
2.2 Sanofi S.A.
2.2.1 Sanofi S.A. Details
2.2.2 Sanofi S.A. Major Business
2.2.3 Sanofi S.A. Anti-Dermatomycosis Treatment Product and Solutions
2.2.4 Sanofi S.A. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Sanofi S.A. Recent Developments and Future Plans
2.3 Novatis AG
2.3.1 Novatis AG Details
2.3.2 Novatis AG Major Business
2.3.3 Novatis AG Anti-Dermatomycosis Treatment Product and Solutions
2.3.4 Novatis AG Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Novatis AG Recent Developments and Future Plans
2.4 Mylan N.V.
2.4.1 Mylan N.V. Details
2.4.2 Mylan N.V. Major Business
2.4.3 Mylan N.V. Anti-Dermatomycosis Treatment Product and Solutions
2.4.4 Mylan N.V. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Mylan N.V. Recent Developments and Future Plans
2.5 Abbott Laboratories
2.5.1 Abbott Laboratories Details
2.5.2 Abbott Laboratories Major Business
2.5.3 Abbott Laboratories Anti-Dermatomycosis Treatment Product and Solutions
2.5.4 Abbott Laboratories Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Abbott Laboratories Recent Developments and Future Plans
2.6 Bayer AG
2.6.1 Bayer AG Details
2.6.2 Bayer AG Major Business
2.6.3 Bayer AG Anti-Dermatomycosis Treatment Product and Solutions
2.6.4 Bayer AG Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Bayer AG Recent Developments and Future Plans
2.7 Eli Lilly and Company
2.7.1 Eli Lilly and Company Details
2.7.2 Eli Lilly and Company Major Business
2.7.3 Eli Lilly and Company Anti-Dermatomycosis Treatment Product and Solutions
2.7.4 Eli Lilly and Company Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Eli Lilly and Company Recent Developments and Future Plans
2.8 AbbVie Inc.
2.8.1 AbbVie Inc. Details
2.8.2 AbbVie Inc. Major Business
2.8.3 AbbVie Inc. Anti-Dermatomycosis Treatment Product and Solutions
2.8.4 AbbVie Inc. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 AbbVie Inc. Recent Developments and Future Plans
2.9 Glaxosmithkline Plc
2.9.1 Glaxosmithkline Plc Details
2.9.2 Glaxosmithkline Plc Major Business
2.9.3 Glaxosmithkline Plc Anti-Dermatomycosis Treatment Product and Solutions
2.9.4 Glaxosmithkline Plc Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Glaxosmithkline Plc Recent Developments and Future Plans
2.10 Janssen Pharmaceuticals, Inc.
2.10.1 Janssen Pharmaceuticals, Inc. Details
2.10.2 Janssen Pharmaceuticals, Inc. Major Business
2.10.3 Janssen Pharmaceuticals, Inc. Anti-Dermatomycosis Treatment Product and Solutions
2.10.4 Janssen Pharmaceuticals, Inc. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Janssen Pharmaceuticals, Inc. Recent Developments and Future Plans
2.11 Taro Pharmaceutical Industries Ltd.
2.11.1 Taro Pharmaceutical Industries Ltd. Details
2.11.2 Taro Pharmaceutical Industries Ltd. Major Business
2.11.3 Taro Pharmaceutical Industries Ltd. Anti-Dermatomycosis Treatment Product and Solutions
2.11.4 Taro Pharmaceutical Industries Ltd. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 Taro Pharmaceutical Industries Ltd. Recent Developments and Future Plans
2.12 Mayne Pharma Group Limited
2.12.1 Mayne Pharma Group Limited Details
2.12.2 Mayne Pharma Group Limited Major Business
2.12.3 Mayne Pharma Group Limited Anti-Dermatomycosis Treatment Product and Solutions
2.12.4 Mayne Pharma Group Limited Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
2.12.5 Mayne Pharma Group Limited Recent Developments and Future Plans
2.13 Viamet Pharmaceuticals, Inc.
2.13.1 Viamet Pharmaceuticals, Inc. Details
2.13.2 Viamet Pharmaceuticals, Inc. Major Business
2.13.3 Viamet Pharmaceuticals, Inc. Anti-Dermatomycosis Treatment Product and Solutions
2.13.4 Viamet Pharmaceuticals, Inc. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
2.13.5 Viamet Pharmaceuticals, Inc. Recent Developments and Future Plans
2.14 Scynexis Inc.
2.14.1 Scynexis Inc. Details
2.14.2 Scynexis Inc. Major Business
2.14.3 Scynexis Inc. Anti-Dermatomycosis Treatment Product and Solutions
2.14.4 Scynexis Inc. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
2.14.5 Scynexis Inc. Recent Developments and Future Plans
2.15 Enzon Pharmaceuticals
2.15.1 Enzon Pharmaceuticals Details
2.15.2 Enzon Pharmaceuticals Major Business
2.15.3 Enzon Pharmaceuticals Anti-Dermatomycosis Treatment Product and Solutions
2.15.4 Enzon Pharmaceuticals Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
2.15.5 Enzon Pharmaceuticals Recent Developments and Future Plans
2.16 Gilead Sciences Inc.
2.16.1 Gilead Sciences Inc. Details
2.16.2 Gilead Sciences Inc. Major Business
2.16.3 Gilead Sciences Inc. Anti-Dermatomycosis Treatment Product and Solutions
2.16.4 Gilead Sciences Inc. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
2.16.5 Gilead Sciences Inc. Recent Developments and Future Plans
3.1 Global Anti-Dermatomycosis Treatment Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Anti-Dermatomycosis Treatment by Company Revenue
3.2.2 Top 3 Anti-Dermatomycosis Treatment Players Market Share in 2023
3.2.3 Top 6 Anti-Dermatomycosis Treatment Players Market Share in 2023
3.3 Anti-Dermatomycosis Treatment Market: Overall Company Footprint Analysis
3.3.1 Anti-Dermatomycosis Treatment Market: Region Footprint
3.3.2 Anti-Dermatomycosis Treatment Market: Company Product Type Footprint
3.3.3 Anti-Dermatomycosis Treatment Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4.1 Global Anti-Dermatomycosis Treatment Consumption Value and Market Share by Type (2019-2024)
4.2 Global Anti-Dermatomycosis Treatment Market Forecast by Type (2025-2030)
5.1 Global Anti-Dermatomycosis Treatment Consumption Value Market Share by Application (2019-2024)
5.2 Global Anti-Dermatomycosis Treatment Market Forecast by Application (2025-2030)
6.1 North America Anti-Dermatomycosis Treatment Consumption Value by Type (2019-2030)
6.2 North America Anti-Dermatomycosis Treatment Consumption Value by Application (2019-2030)
6.3 North America Anti-Dermatomycosis Treatment Market Size by Country
6.3.1 North America Anti-Dermatomycosis Treatment Consumption Value by Country (2019-2030)
6.3.2 United States Anti-Dermatomycosis Treatment Market Size and Forecast (2019-2030)
6.3.3 Canada Anti-Dermatomycosis Treatment Market Size and Forecast (2019-2030)
6.3.4 Mexico Anti-Dermatomycosis Treatment Market Size and Forecast (2019-2030)
7.1 Europe Anti-Dermatomycosis Treatment Consumption Value by Type (2019-2030)
7.2 Europe Anti-Dermatomycosis Treatment Consumption Value by Application (2019-2030)
7.3 Europe Anti-Dermatomycosis Treatment Market Size by Country
7.3.1 Europe Anti-Dermatomycosis Treatment Consumption Value by Country (2019-2030)
7.3.2 Germany Anti-Dermatomycosis Treatment Market Size and Forecast (2019-2030)
7.3.3 France Anti-Dermatomycosis Treatment Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Anti-Dermatomycosis Treatment Market Size and Forecast (2019-2030)
7.3.5 Russia Anti-Dermatomycosis Treatment Market Size and Forecast (2019-2030)
7.3.6 Italy Anti-Dermatomycosis Treatment Market Size and Forecast (2019-2030)
8.1 Asia-Pacific Anti-Dermatomycosis Treatment Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Anti-Dermatomycosis Treatment Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Anti-Dermatomycosis Treatment Market Size by Region
8.3.1 Asia-Pacific Anti-Dermatomycosis Treatment Consumption Value by Region (2019-2030)
8.3.2 China Anti-Dermatomycosis Treatment Market Size and Forecast (2019-2030)
8.3.3 Japan Anti-Dermatomycosis Treatment Market Size and Forecast (2019-2030)
8.3.4 South Korea Anti-Dermatomycosis Treatment Market Size and Forecast (2019-2030)
8.3.5 India Anti-Dermatomycosis Treatment Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Anti-Dermatomycosis Treatment Market Size and Forecast (2019-2030)
8.3.7 Australia Anti-Dermatomycosis Treatment Market Size and Forecast (2019-2030)
9.1 South America Anti-Dermatomycosis Treatment Consumption Value by Type (2019-2030)
9.2 South America Anti-Dermatomycosis Treatment Consumption Value by Application (2019-2030)
9.3 South America Anti-Dermatomycosis Treatment Market Size by Country
9.3.1 South America Anti-Dermatomycosis Treatment Consumption Value by Country (2019-2030)
9.3.2 Brazil Anti-Dermatomycosis Treatment Market Size and Forecast (2019-2030)
9.3.3 Argentina Anti-Dermatomycosis Treatment Market Size and Forecast (2019-2030)
10.1 Middle East & Africa Anti-Dermatomycosis Treatment Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Anti-Dermatomycosis Treatment Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Anti-Dermatomycosis Treatment Market Size by Country
10.3.1 Middle East & Africa Anti-Dermatomycosis Treatment Consumption Value by Country (2019-2030)
10.3.2 Turkey Anti-Dermatomycosis Treatment Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Anti-Dermatomycosis Treatment Market Size and Forecast (2019-2030)
10.3.4 UAE Anti-Dermatomycosis Treatment Market Size and Forecast (2019-2030)
11.1 Anti-Dermatomycosis Treatment Market Drivers
11.2 Anti-Dermatomycosis Treatment Market Restraints
11.3 Anti-Dermatomycosis Treatment Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12.1 Anti-Dermatomycosis Treatment Industry Chain
12.2 Anti-Dermatomycosis Treatment Upstream Analysis
12.3 Anti-Dermatomycosis Treatment Midstream Analysis
12.4 Anti-Dermatomycosis Treatment Downstream Analysis
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table of Figures
List of Tables
Table 1. Global Anti-Dermatomycosis Treatment Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Anti-Dermatomycosis Treatment Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Global Anti-Dermatomycosis Treatment Consumption Value by Region (2019-2024) & (USD Million)
Table 4. Global Anti-Dermatomycosis Treatment Consumption Value by Region (2025-2030) & (USD Million)
Table 5. Pfizer Inc. Company Information, Head Office, and Major Competitors
Table 6. Pfizer Inc. Major Business
Table 7. Pfizer Inc. Anti-Dermatomycosis Treatment Product and Solutions
Table 8. Pfizer Inc. Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 9. Pfizer Inc. Recent Developments and Future Plans
Table 10. Sanofi S.A. Company Information, Head Office, and Major Competitors
Table 11. Sanofi S.A. Major Business
Table 12. Sanofi S.A. Anti-Dermatomycosis Treatment Product and Solutions
Table 13. Sanofi S.A. Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 14. Sanofi S.A. Recent Developments and Future Plans
Table 15. Novatis AG Company Information, Head Office, and Major Competitors
Table 16. Novatis AG Major Business
Table 17. Novatis AG Anti-Dermatomycosis Treatment Product and Solutions
Table 18. Novatis AG Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 19. Novatis AG Recent Developments and Future Plans
Table 20. Mylan N.V. Company Information, Head Office, and Major Competitors
Table 21. Mylan N.V. Major Business
Table 22. Mylan N.V. Anti-Dermatomycosis Treatment Product and Solutions
Table 23. Mylan N.V. Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 24. Mylan N.V. Recent Developments and Future Plans
Table 25. Abbott Laboratories Company Information, Head Office, and Major Competitors
Table 26. Abbott Laboratories Major Business
Table 27. Abbott Laboratories Anti-Dermatomycosis Treatment Product and Solutions
Table 28. Abbott Laboratories Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 29. Abbott Laboratories Recent Developments and Future Plans
Table 30. Bayer AG Company Information, Head Office, and Major Competitors
Table 31. Bayer AG Major Business
Table 32. Bayer AG Anti-Dermatomycosis Treatment Product and Solutions
Table 33. Bayer AG Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 34. Bayer AG Recent Developments and Future Plans
Table 35. Eli Lilly and Company Company Information, Head Office, and Major Competitors
Table 36. Eli Lilly and Company Major Business
Table 37. Eli Lilly and Company Anti-Dermatomycosis Treatment Product and Solutions
Table 38. Eli Lilly and Company Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 39. Eli Lilly and Company Recent Developments and Future Plans
Table 40. AbbVie Inc. Company Information, Head Office, and Major Competitors
Table 41. AbbVie Inc. Major Business
Table 42. AbbVie Inc. Anti-Dermatomycosis Treatment Product and Solutions
Table 43. AbbVie Inc. Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 44. AbbVie Inc. Recent Developments and Future Plans
Table 45. Glaxosmithkline Plc Company Information, Head Office, and Major Competitors
Table 46. Glaxosmithkline Plc Major Business
Table 47. Glaxosmithkline Plc Anti-Dermatomycosis Treatment Product and Solutions
Table 48. Glaxosmithkline Plc Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 49. Glaxosmithkline Plc Recent Developments and Future Plans
Table 50. Janssen Pharmaceuticals, Inc. Company Information, Head Office, and Major Competitors
Table 51. Janssen Pharmaceuticals, Inc. Major Business
Table 52. Janssen Pharmaceuticals, Inc. Anti-Dermatomycosis Treatment Product and Solutions
Table 53. Janssen Pharmaceuticals, Inc. Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 54. Janssen Pharmaceuticals, Inc. Recent Developments and Future Plans
Table 55. Taro Pharmaceutical Industries Ltd. Company Information, Head Office, and Major Competitors
Table 56. Taro Pharmaceutical Industries Ltd. Major Business
Table 57. Taro Pharmaceutical Industries Ltd. Anti-Dermatomycosis Treatment Product and Solutions
Table 58. Taro Pharmaceutical Industries Ltd. Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 59. Taro Pharmaceutical Industries Ltd. Recent Developments and Future Plans
Table 60. Mayne Pharma Group Limited Company Information, Head Office, and Major Competitors
Table 61. Mayne Pharma Group Limited Major Business
Table 62. Mayne Pharma Group Limited Anti-Dermatomycosis Treatment Product and Solutions
Table 63. Mayne Pharma Group Limited Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 64. Mayne Pharma Group Limited Recent Developments and Future Plans
Table 65. Viamet Pharmaceuticals, Inc. Company Information, Head Office, and Major Competitors
Table 66. Viamet Pharmaceuticals, Inc. Major Business
Table 67. Viamet Pharmaceuticals, Inc. Anti-Dermatomycosis Treatment Product and Solutions
Table 68. Viamet Pharmaceuticals, Inc. Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 69. Viamet Pharmaceuticals, Inc. Recent Developments and Future Plans
Table 70. Scynexis Inc. Company Information, Head Office, and Major Competitors
Table 71. Scynexis Inc. Major Business
Table 72. Scynexis Inc. Anti-Dermatomycosis Treatment Product and Solutions
Table 73. Scynexis Inc. Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 74. Scynexis Inc. Recent Developments and Future Plans
Table 75. Enzon Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 76. Enzon Pharmaceuticals Major Business
Table 77. Enzon Pharmaceuticals Anti-Dermatomycosis Treatment Product and Solutions
Table 78. Enzon Pharmaceuticals Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 79. Enzon Pharmaceuticals Recent Developments and Future Plans
Table 80. Gilead Sciences Inc. Company Information, Head Office, and Major Competitors
Table 81. Gilead Sciences Inc. Major Business
Table 82. Gilead Sciences Inc. Anti-Dermatomycosis Treatment Product and Solutions
Table 83. Gilead Sciences Inc. Anti-Dermatomycosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 84. Gilead Sciences Inc. Recent Developments and Future Plans
Table 85. Global Anti-Dermatomycosis Treatment Revenue (USD Million) by Players (2019-2024)
Table 86. Global Anti-Dermatomycosis Treatment Revenue Share by Players (2019-2024)
Table 87. Breakdown of Anti-Dermatomycosis Treatment by Company Type (Tier 1, Tier 2, and Tier 3)
Table 88. Market Position of Players in Anti-Dermatomycosis Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 89. Head Office of Key Anti-Dermatomycosis Treatment Players
Table 90. Anti-Dermatomycosis Treatment Market: Company Product Type Footprint
Table 91. Anti-Dermatomycosis Treatment Market: Company Product Application Footprint
Table 92. Anti-Dermatomycosis Treatment New Market Entrants and Barriers to Market Entry
Table 93. Anti-Dermatomycosis Treatment Mergers, Acquisition, Agreements, and Collaborations
Table 94. Global Anti-Dermatomycosis Treatment Consumption Value (USD Million) by Type (2019-2024)
Table 95. Global Anti-Dermatomycosis Treatment Consumption Value Share by Type (2019-2024)
Table 96. Global Anti-Dermatomycosis Treatment Consumption Value Forecast by Type (2025-2030)
Table 97. Global Anti-Dermatomycosis Treatment Consumption Value by Application (2019-2024)
Table 98. Global Anti-Dermatomycosis Treatment Consumption Value Forecast by Application (2025-2030)
Table 99. North America Anti-Dermatomycosis Treatment Consumption Value by Type (2019-2024) & (USD Million)
Table 100. North America Anti-Dermatomycosis Treatment Consumption Value by Type (2025-2030) & (USD Million)
Table 101. North America Anti-Dermatomycosis Treatment Consumption Value by Application (2019-2024) & (USD Million)
Table 102. North America Anti-Dermatomycosis Treatment Consumption Value by Application (2025-2030) & (USD Million)
Table 103. North America Anti-Dermatomycosis Treatment Consumption Value by Country (2019-2024) & (USD Million)
Table 104. North America Anti-Dermatomycosis Treatment Consumption Value by Country (2025-2030) & (USD Million)
Table 105. Europe Anti-Dermatomycosis Treatment Consumption Value by Type (2019-2024) & (USD Million)
Table 106. Europe Anti-Dermatomycosis Treatment Consumption Value by Type (2025-2030) & (USD Million)
Table 107. Europe Anti-Dermatomycosis Treatment Consumption Value by Application (2019-2024) & (USD Million)
Table 108. Europe Anti-Dermatomycosis Treatment Consumption Value by Application (2025-2030) & (USD Million)
Table 109. Europe Anti-Dermatomycosis Treatment Consumption Value by Country (2019-2024) & (USD Million)
Table 110. Europe Anti-Dermatomycosis Treatment Consumption Value by Country (2025-2030) & (USD Million)
Table 111. Asia-Pacific Anti-Dermatomycosis Treatment Consumption Value by Type (2019-2024) & (USD Million)
Table 112. Asia-Pacific Anti-Dermatomycosis Treatment Consumption Value by Type (2025-2030) & (USD Million)
Table 113. Asia-Pacific Anti-Dermatomycosis Treatment Consumption Value by Application (2019-2024) & (USD Million)
Table 114. Asia-Pacific Anti-Dermatomycosis Treatment Consumption Value by Application (2025-2030) & (USD Million)
Table 115. Asia-Pacific Anti-Dermatomycosis Treatment Consumption Value by Region (2019-2024) & (USD Million)
Table 116. Asia-Pacific Anti-Dermatomycosis Treatment Consumption Value by Region (2025-2030) & (USD Million)
Table 117. South America Anti-Dermatomycosis Treatment Consumption Value by Type (2019-2024) & (USD Million)
Table 118. South America Anti-Dermatomycosis Treatment Consumption Value by Type (2025-2030) & (USD Million)
Table 119. South America Anti-Dermatomycosis Treatment Consumption Value by Application (2019-2024) & (USD Million)
Table 120. South America Anti-Dermatomycosis Treatment Consumption Value by Application (2025-2030) & (USD Million)
Table 121. South America Anti-Dermatomycosis Treatment Consumption Value by Country (2019-2024) & (USD Million)
Table 122. South America Anti-Dermatomycosis Treatment Consumption Value by Country (2025-2030) & (USD Million)
Table 123. Middle East & Africa Anti-Dermatomycosis Treatment Consumption Value by Type (2019-2024) & (USD Million)
Table 124. Middle East & Africa Anti-Dermatomycosis Treatment Consumption Value by Type (2025-2030) & (USD Million)
Table 125. Middle East & Africa Anti-Dermatomycosis Treatment Consumption Value by Application (2019-2024) & (USD Million)
Table 126. Middle East & Africa Anti-Dermatomycosis Treatment Consumption Value by Application (2025-2030) & (USD Million)
Table 127. Middle East & Africa Anti-Dermatomycosis Treatment Consumption Value by Country (2019-2024) & (USD Million)
Table 128. Middle East & Africa Anti-Dermatomycosis Treatment Consumption Value by Country (2025-2030) & (USD Million)
Table 129. Anti-Dermatomycosis Treatment Raw Material
Table 130. Key Suppliers of Anti-Dermatomycosis Treatment Raw Materials
List of Figures
Figure 1. Anti-Dermatomycosis Treatment Picture
Figure 2. Global Anti-Dermatomycosis Treatment Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Anti-Dermatomycosis Treatment Consumption Value Market Share by Type in 2023
Figure 4. Polyens
Figure 5. Azoles
Figure 6. Allylamines
Figure 7. Echinocandins
Figure 8. Others
Figure 9. Global Anti-Dermatomycosis Treatment Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 10. Anti-Dermatomycosis Treatment Consumption Value Market Share by Application in 2023
Figure 11. Tinea Corporis Picture
Figure 12. Tinea Unguium Picture
Figure 13. Aspergillosis Picture
Figure 14. Tinea Capitis Picture
Figure 15. Others Picture
Figure 16. Global Anti-Dermatomycosis Treatment Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 17. Global Anti-Dermatomycosis Treatment Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 18. Global Market Anti-Dermatomycosis Treatment Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
Figure 19. Global Anti-Dermatomycosis Treatment Consumption Value Market Share by Region (2019-2030)
Figure 20. Global Anti-Dermatomycosis Treatment Consumption Value Market Share by Region in 2023
Figure 21. North America Anti-Dermatomycosis Treatment Consumption Value (2019-2030) & (USD Million)
Figure 22. Europe Anti-Dermatomycosis Treatment Consumption Value (2019-2030) & (USD Million)
Figure 23. Asia-Pacific Anti-Dermatomycosis Treatment Consumption Value (2019-2030) & (USD Million)
Figure 24. South America Anti-Dermatomycosis Treatment Consumption Value (2019-2030) & (USD Million)
Figure 25. Middle East and Africa Anti-Dermatomycosis Treatment Consumption Value (2019-2030) & (USD Million)
Figure 26. Global Anti-Dermatomycosis Treatment Revenue Share by Players in 2023
Figure 27. Anti-Dermatomycosis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
Figure 28. Global Top 3 Players Anti-Dermatomycosis Treatment Market Share in 2023
Figure 29. Global Top 6 Players Anti-Dermatomycosis Treatment Market Share in 2023
Figure 30. Global Anti-Dermatomycosis Treatment Consumption Value Share by Type (2019-2024)
Figure 31. Global Anti-Dermatomycosis Treatment Market Share Forecast by Type (2025-2030)
Figure 32. Global Anti-Dermatomycosis Treatment Consumption Value Share by Application (2019-2024)
Figure 33. Global Anti-Dermatomycosis Treatment Market Share Forecast by Application (2025-2030)
Figure 34. North America Anti-Dermatomycosis Treatment Consumption Value Market Share by Type (2019-2030)
Figure 35. North America Anti-Dermatomycosis Treatment Consumption Value Market Share by Application (2019-2030)
Figure 36. North America Anti-Dermatomycosis Treatment Consumption Value Market Share by Country (2019-2030)
Figure 37. United States Anti-Dermatomycosis Treatment Consumption Value (2019-2030) & (USD Million)
Figure 38. Canada Anti-Dermatomycosis Treatment Consumption Value (2019-2030) & (USD Million)
Figure 39. Mexico Anti-Dermatomycosis Treatment Consumption Value (2019-2030) & (USD Million)
Figure 40. Europe Anti-Dermatomycosis Treatment Consumption Value Market Share by Type (2019-2030)
Figure 41. Europe Anti-Dermatomycosis Treatment Consumption Value Market Share by Application (2019-2030)
Figure 42. Europe Anti-Dermatomycosis Treatment Consumption Value Market Share by Country (2019-2030)
Figure 43. Germany Anti-Dermatomycosis Treatment Consumption Value (2019-2030) & (USD Million)
Figure 44. France Anti-Dermatomycosis Treatment Consumption Value (2019-2030) & (USD Million)
Figure 45. United Kingdom Anti-Dermatomycosis Treatment Consumption Value (2019-2030) & (USD Million)
Figure 46. Russia Anti-Dermatomycosis Treatment Consumption Value (2019-2030) & (USD Million)
Figure 47. Italy Anti-Dermatomycosis Treatment Consumption Value (2019-2030) & (USD Million)
Figure 48. Asia-Pacific Anti-Dermatomycosis Treatment Consumption Value Market Share by Type (2019-2030)
Figure 49. Asia-Pacific Anti-Dermatomycosis Treatment Consumption Value Market Share by Application (2019-2030)
Figure 50. Asia-Pacific Anti-Dermatomycosis Treatment Consumption Value Market Share by Region (2019-2030)
Figure 51. China Anti-Dermatomycosis Treatment Consumption Value (2019-2030) & (USD Million)
Figure 52. Japan Anti-Dermatomycosis Treatment Consumption Value (2019-2030) & (USD Million)
Figure 53. South Korea Anti-Dermatomycosis Treatment Consumption Value (2019-2030) & (USD Million)
Figure 54. India Anti-Dermatomycosis Treatment Consumption Value (2019-2030) & (USD Million)
Figure 55. Southeast Asia Anti-Dermatomycosis Treatment Consumption Value (2019-2030) & (USD Million)
Figure 56. Australia Anti-Dermatomycosis Treatment Consumption Value (2019-2030) & (USD Million)
Figure 57. South America Anti-Dermatomycosis Treatment Consumption Value Market Share by Type (2019-2030)
Figure 58. South America Anti-Dermatomycosis Treatment Consumption Value Market Share by Application (2019-2030)
Figure 59. South America Anti-Dermatomycosis Treatment Consumption Value Market Share by Country (2019-2030)
Figure 60. Brazil Anti-Dermatomycosis Treatment Consumption Value (2019-2030) & (USD Million)
Figure 61. Argentina Anti-Dermatomycosis Treatment Consumption Value (2019-2030) & (USD Million)
Figure 62. Middle East and Africa Anti-Dermatomycosis Treatment Consumption Value Market Share by Type (2019-2030)
Figure 63. Middle East and Africa Anti-Dermatomycosis Treatment Consumption Value Market Share by Application (2019-2030)
Figure 64. Middle East and Africa Anti-Dermatomycosis Treatment Consumption Value Market Share by Country (2019-2030)
Figure 65. Turkey Anti-Dermatomycosis Treatment Consumption Value (2019-2030) & (USD Million)
Figure 66. Saudi Arabia Anti-Dermatomycosis Treatment Consumption Value (2019-2030) & (USD Million)
Figure 67. UAE Anti-Dermatomycosis Treatment Consumption Value (2019-2030) & (USD Million)
Figure 68. Anti-Dermatomycosis Treatment Market Drivers
Figure 69. Anti-Dermatomycosis Treatment Market Restraints
Figure 70. Anti-Dermatomycosis Treatment Market Trends
Figure 71. Porters Five Forces Analysis
Figure 72. Manufacturing Cost Structure Analysis of Anti-Dermatomycosis Treatment in 2023
Figure 73. Manufacturing Process Analysis of Anti-Dermatomycosis Treatment
Figure 74. Anti-Dermatomycosis Treatment Industrial Chain
Figure 75. Methodology
Figure 76. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Pfizer Inc. Sanofi S.A. Novatis AG Mylan N.V. Abbott Laboratories Bayer AG Eli Lilly and Company AbbVie Inc. Glaxosmithkline Plc Janssen Pharmaceuticals, Inc. Taro Pharmaceutical Industries Ltd. Mayne Pharma Group Limited Viamet Pharmaceuticals, Inc. Scynexis Inc. Enzon Pharmaceuticals Gilead Sciences Inc.
Related Reports
01 Sep 2023
Medical Devices & Consumables
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
